CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to enhancing the treatment of cancer and other diseases by harnessing the power of the human immune system. The company's lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is a novel immunotherapy being developed as a potential first-line neoadjuvant treatment for patients with advanced primary head and neck cancer. CEL-SCI's approach aims to stimulate the body's natural ability to fight disease, with a focus on improving patient outcomes and quality of life. The company is also exploring the utility of its LEAPS™ (Ligand Epitope Antigen Presentation System) technology for developing vaccines for infectious diseases and autoimmune disorders.
The headquarters serves as the central hub for corporate administration, strategic leadership, investor relations, financial operations, and regulatory affairs management.
Situated in a modern office complex within a well-established business park, offering a professional environment and good transportation links. The focus is on functional office space suited for corporate operations.
The work culture at CEL-SCI's headquarters is likely characterized by a strong sense of purpose, driven by the pursuit of scientific innovation and the development of life-changing therapies. It likely fosters collaboration, dedication, and a focus on achieving clinical and regulatory milestones.
Its location in the greater Washington D.C. area provides strategic advantages, including proximity to regulatory agencies like the U.S. Food and Drug Administration (FDA), access to a skilled talent pool, and connections with the broader biotech and investment community.
While CEL-SCI's core administrative, research, and manufacturing operations are based in the United States (Virginia and Maryland), its clinical development program for Multikine has a significant global reach. The pivotal Phase 3 study for Multikine in head and neck cancer involved clinical trial sites in numerous countries across North America, Europe, and Asia. This international clinical trial footprint underscores CEL-SCI's strategy to develop therapies for global patient populations and to seek regulatory approvals in multiple major markets worldwide. The company's global presence is primarily driven by its clinical research activities and collaborations rather than a network of international offices.
8229 Boone Boulevard, Suite 802
Vienna
Virginia
USA
Address: Specific address for the manufacturing/R&D facility near Baltimore (e.g., 1450 South Rolling Road, Baltimore, MD 21227, though this is a research park address they lease space in; exact dedicated facility address might be less public). The company leases approximately 41,000 square feet.
Located in the Maryland biotech corridor, this site benefits from access to specialized scientific talent, research institutions, and infrastructure supportive of biopharmaceutical manufacturing and R&D.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cel-Sci' leadership includes:
Cel-Sci has been backed by several prominent investors over the years, including:
In the past year, CEL-SCI Corporation strengthened its executive team with a key appointment in financial leadership, appointing a new Chief Financial Officer.
Discover the tools Cel-Sci uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
CEL-SCI Corporation's email addresses likely follow common corporate patterns, typically combining elements of an employee's name with the company domain 'cel-sci.com'. Standard formats facilitate professional communication.
Common formats include [firstinitial][lastname]@cel-sci.com (e.g., jdoe@cel-sci.com) or [first].[lastname]@cel-sci.com (e.g., jane.doe@cel-sci.com).
Format
info@cel-sci.com (General contact, other specific emails may follow patterns like jsmith@cel-sci.com)
Example
70%
Success rate
GlobeNewswire • May 15, 2024
CEL-SCI Corporation announced its financial results for the quarter ended March 31, 2024, and provided updates on its Multikine clinical development program, including interactions with regulatory authorities and manufacturing activities....more
SEC Filing • April 29, 2024
CEL-SCI filed its definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission for its 2024 Annual Meeting of Stockholders, detailing proposals for stockholder voting....more
GlobeNewswire • December 18, 2023
CEL-SCI announced the appointment of Jonathan F. Hale as its new Chief Financial Officer, effective December 18, 2023. Mr. Hale brings over 20 years of financial and operational experience to the role....more
GlobeNewswire • February 14, 2024
CEL-SCI Corporation reported its financial results for the first fiscal quarter ended December 31, 2023, and provided a corporate update on its programs....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cel-Sci, are just a search away.